Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus irinotecan and temozolomide versus irinotecan and temozolomide in recurrent or refractory Ewing sarcoma
NL-OMON56430Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Aug 2022
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Ewing sarcoma comparing Palbociclib + irinotecan + temozolomide with Irinotecan + temozolomide (2 arms). Primary endpoint: Event-free survival. Planned start Aug 2022; status: withdrawn.
02
Drugs
palbociclibirinotecantemozolomide
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NL-OMON56430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56430.